Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
NCT Number: NCT00910767
The main objective of this study is to evaluate the feasibility of closed loop insulin pump therapy to improve overnight glucose control in adults with type 1 diabetes.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Cambridge, CB2 0QQ, United Kingdom
People with type 1 diabetes(T1D) need regular insulin injections or continuous delivery of insulin using an insulin pump in order to keep the blood glucose levels normal. We know that keeping blood sugars in the normal range will help prevent long term diabetes related complications involving the eyes, kidneys and heart. However, achieving treatment goals can be very difficult as the tighter we try to control blood glucose levels, the greater the risk of the person developing episodes of low glucose levels (hypoglycaemia). This is a particular problem at night and one solution is to develop a system whereby the amount of insulin injected is very closely matched to the blood sugar levels on a continuous basis. This can be achieved by what is called a "closed loop system" where a small glucose sensor placed under the skin communicates with a computer containing an algorithm that drives an insulin pump. This system is being developed in Cambridge and we have trialed this on 16 children and adolescents with T1D in a clinical setting over the past year. We have found that this system is very effective at preventing hypoglycaemia in this group of patients.
We will recruit 12 adults with T1D on insulin pump therapy, and the studies will be done in a clinical research facility. The subjects will be studied on two nights. On one night they will have their normal insulin pump therapy and on the other night their insulin pump will be varied according to information about blood glucose values from the continuous glucose sensor. This information will be manually typed into the computer every 15 minutes from 8pm until 8am. The algorithm will advise of the insulin infusion rate and this will be manually changed by a trained nurse every 15 minutes throughout the night.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subcutaneous delivery of Novorapid insulin according to usual pump regime
Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
Time frame: 1900 to 0800hr
Time frame: 1900 to 0800hr
Time frame: 0000 to 0800hr
Time frame: 0800 to 1200hr
Time frame: 1900 to 0800hr
Time frame: 0000 to 0800hr
Time frame: 0800 to 1200hr
Time frame: 1900 to 0800hr
Time frame: 0000 to 0800hr
Time frame: 0800 to 1200hr
Time frame: 1900 to 0800hr
Time frame: 0000 to 0800hr
Time frame: 0800 to 1200hr
Time frame: 1900 to 0800hr
Time frame: 0000 to 0800hr
Time frame: 0800 to 1200hr
Time frame: 1900 to 0800hr
Time frame: 1900 to 0800hr
Time frame: 1900 to 0800hr
Time frame: 0000 to 0800hr
Time frame: 0800 to 1200hr
Time frame: 0000 to 0800hr
Time frame: 0800 to 1200hr
Time frame: 1900 to 0800hr
Time frame: 0000 to 0800hr
Time frame: 0800 to 1200hr
University of Cambridge
Other
A Randomised, 2-period Cross-over Study to Assess the Feasibility of Overnight Computer-based Glucose Control Based on Continuous Subcutaneous Glucose Monitoring, and Compare it With Conventional Pump Therapy in Adults With Type 1 Diabetes
Acronym: ANGELA01
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05488119
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT07696780
Autoimmune Diseases, Diabetes Mellitus
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT05610111
Autoimmune Diseases, Diabetes Mellitus
Charlottesville, Virginia, United States
View Trial DetailsNCT06308549
Autoimmune Diseases, Diabetes Distress
Bad Mergentheim, Baden-Wurttemberg, Germany
View Trial Details